赛诺菲(SNY) - 2023 Q3 - Quarterly Report

Press Release Specialty Care growth, strong launch uptake of Beyfortus® and ALTUVIIIO® drive solid Q3 results Paris, October 27, 2023 Q3 2023 sales growth of 3.2% at CER and business EPS(1) decrease of 2.1% at CER • Specialty Care grew 13.5% driven by Dupixent® (€2,847 million, +32.8%) and ALTUVIIIO® more than offsetting the impact of Aubagio® generic competition in the U.S. • Stable Vaccines sales (-0.6%) benefited from strong Beyfortus® launch offsetting lower influenza vaccines sales • General Medicines ...